NCT07766512Not yet recruiting
Five-year Follow-up After Sars-CoV-2 Infection: Prevalence and Evolution of Post-acute Sequalae of COVID-19 (PASC)
Source: ClinicalTrials.gov · Last updated 14 Aug 2026
Brief summary (registry, in English)
This multicenter, observational, retrospective-prospective study aims to evaluate the prevalence and trajectory of Post-Acute Sequelae of COVID-19 (PASC) approximately 5 years after SARS-CoV-2 infection. The study will re-contact participants from an established cohort of more than 3,000 individuals with microbiologically confirmed SARS-CoV-2 infection, including both hospitalized and non-hospitalized patients, previously followed in dedicated post-COVID outpatient clinics. Participants will undergo a structured telephone interview approximately 60 ± 3 months after infection, and those meeting predefined clinical criteria will be invited to an in-person clinical assessment. The study will evaluate persistent symptoms, functional status, cognitive and nutritional status, frailty, sarcopenia, quality of life, healthcare resource utilization, and direct and indirect healthcare costs to characterize the long-term trajectory of PASC.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 900 (estimated)
- First submitted
- 29 Jul 2026
- Start date
- 1 Sept 2026
- Primary completion date
- 1 Sept 2029
- Lead sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Diseases
- Long COVID and ME/CFS
- NCT number
- NCT07766512
What you commit to
- Study type: Observational
- Planned participants: 900
- From 1 Sept 2026 to the primary completion date, 1 Sept 2029
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Failure to provide informed consent.
Other
- Inability or refusal to complete follow-up procedures due to clinical, cognitive, or logistical reasons incompatible with the collection of essential study data.
- Persistent inability to establish contact after multiple documented attempts.
Who the study is looking for
- Age ≥ 18 years.
- Previous participation in the original cohort assessed at 6-12 months after the initial SARS-CoV-2 infection.
- Persistence of symptoms beyond 3 months after infection, consistent with the WHO definition of Post-Acute Sequelae of COVID-19 (PASC).
- Availability of clinical data related to the initial follow-up phase.
- Provision of informed consent for study participation (for patients enrolled in the prospective cohort, informed consent will be obtained, while for retrospective participants, reference will be made to Article 110-bis of the Italian Privacy Code).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.